Effect of genetic polymorphisms on therapeutic response in multiple sclerosis relapsing-remitting patients treated with interferon-beta.
Mutat Res Rev Mutat Res
; 785: 108322, 2020.
Article
en En
| MEDLINE
| ID: mdl-32800273
ABSTRACT
Treatment with interferon beta (IFNß) is one of the first-line treatments for multiple sclerosis. In clinical practice, however, many patients present suboptimal response to IFNß, with the proportion of non-responders ranging from 20 to 50%. This variable response can be affected by genetic factors, such as polymorphisms in the genes involved in the disease state, pharmacodynamics, metabolism or in the action mechanism of IFNß, which can affect the efficacy of this drug. This review assesses the impact of pharmacogenetics studies on response to IFNß treatment among patients diagnosed with relapsing-remitting multiple sclerosis (RRMS). The results suggest that the detection of polymorphisms in several genes (CD46, CD58, FHIT, IRF5, GAPVD1, GPC5, GRBRB3, MxA, PELI3 and ZNF697) could be used in the future as predictive markers of response to IFNß treatment in patients diagnosed with RRMS. However, few studies have been carried out and they have been performed on small sample sizes, which makes it difficult to generalize the role of these genes in IFNß treatment. Studies on large sample sizes with longer term follow-up are therefore required to confirm these results.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Polimorfismo Genético
/
Marcadores Genéticos
/
Interferón beta
/
Esclerosis Múltiple Recurrente-Remitente
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Mutat Res Rev Mutat Res
Año:
2020
Tipo del documento:
Article